Neutrophil Modulation in Alpha-1 Antitrypsin Deficiency
- PMID: 32697897
- PMCID: PMC7857711
- DOI: 10.15326/jcopdf.7.3.2019.0164
Neutrophil Modulation in Alpha-1 Antitrypsin Deficiency
Abstract
Neutrophils have been implicated in the pathogenesis of alpha-1 antitrypsin deficiency (AATD) since the first descriptions of the disease. Neutrophil proteinases can cause all lung manifestations of AATD, from small airways destruction, to emphysema, to chronic bronchitis and airflow obstruction. Initially, it was proposed that neutrophil functions were normal in AATD, responding in an initially physiological manner to a high burden of pulmonary inflammation. More recent studies have shed new light on this, describing changes in neutrophil responses (a modulation of usual cellular functions) in the presence of inflammation or infection which might enhance tissue damage while impeding bacterial clearance, providing some evidence to support there being an AATD neutrophil phenotype. Many facets of neutrophil function in AATD can be explained by the loss of alpha-1 antitrypsin (AAT) in diverse biological processes. If this were the only reason for altered neutrophil functions, one would predict similar disease presentation across affected people. However, this is not the case. Despite similar (low) levels of AAT, lung disease is extremely variable in AATD, with some patients suffering a significant burden of lung disease and some much less, irrespective of smoking habits and, in some cases, despite augmentation therapy. This review will explore how complex neutrophil responses are and how they are altered with age, inflammation and AATD. Further, it will discuss the need to understand more completely which aspects of AATD-associated disease are driven by neutrophils and how patients more susceptible to neutrophil dysfunction could be identified to potentially stratify treatment approaches.
Keywords: alpha-1 antitrypsin deficiency; bronchitis; chronic obstructive pulmonary disease; copd; emphysema; exacerbations; proteinases.
JCOPDF © 2020.
Conflict of interest statement
Dr Sapey reports grants from the Alpha-1 Foundation, Wellcome Trust, Medical Research Council, British Lung Foundation and the National Institute of Health Research. She has no other conflicts of interest.
References
-
- Jacobsson KI. Studies on the determination of fibrinogen in human blood plasma. II. Studies on the trypsin and plasmin inhibitors in human blood serum. Scand J Clin Lab Invest. 1955;7:3-102. - PubMed
-
- Drew W,Wilson DV,Sapey E. Inflammation and neutrophil immunosenescence in health and disease: Targeted treatments to improve clinical outcomes in the elderly. Exp Gerontol. 2018;105:70-77. doi: https://doi.org/10.1016/j.exger.2017.12.020 - PubMed
-
- Brezski RJ,Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: An evasion tactic against host immunity?. mAbs. 2010;2(3):212-220. doi: https://doi.org/10.4161/mabs.2.3.11780 - PMC - PubMed
-
- Butler A,Walton GM,Sapey E. Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease. COPD. 2018;15(4):1-13. - PubMed
-
- Joslin G,Griffin GL,August AM,et al. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide. J Clin Invest. 1992;90(3):1150-1154. doi: https://doi.org/10.1172/JCI115934 - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous